Spike-specific T cell immunity following vaccination against the human coronaviruses SARS-CoV-2 and MERS-CoV
- Weitere Titel
-
Spike-spezifische T-Zellen-Immunität nach Impfung gegen die humanen Coronaviren SARS-CoV-2 und MERS-CoV
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Hamburg, Universität Hamburg, Dissertation, 2024
- Schlagwort
-
Impfstoff
T-Lymphozyt
Coronaviren
Zelluläre Immunität
SARS-CoV-2
Immunsuppression
- Ereignis
-
Veröffentlichung
- (wo)
-
Hamburg
- (wer)
-
Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
- (wann)
-
2024
- Urheber
-
Mayer, Leonie
- Beteiligte Personen und Organisationen
-
Addo, Marylyn Martina
Schmidt-Chanasit, Jonas
- URN
-
urn:nbn:de:gbv:18-ediss-117098
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:50 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mayer, Leonie
- Addo, Marylyn Martina
- Schmidt-Chanasit, Jonas
- Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
Entstanden
- 2024
Ähnliche Objekte (12)
Emergence of SARS‐CoV‐2 spike protein at the vaccination site
Functional analysis of the MERS-coronavirus spike protein
"TMC" "SPiKE" "CoBRA"
Dance, politics & co-immunity
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
SARS-CoV-2 immunity through vaccination and infection in healthy individuals and haemodialysis patients
Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients
Characterization of B cell and antibody responses induced by vaccination against the human coronaviruses MERS-CoV and SARS-CoV-2
Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
Spike Dickus & Co : Geschichten von ganz besonderen Tieren
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
"SPiKe" ONE CoBRA GSE | NICH SAUBER MACHEN!!!!..
Emergence of SARS‐CoV‐2 spike protein at the vaccination site
Functional analysis of the MERS-coronavirus spike protein
"TMC" "SPiKE" "CoBRA"
Dance, politics & co-immunity
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
SARS-CoV-2 immunity through vaccination and infection in healthy individuals and haemodialysis patients
Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients
Characterization of B cell and antibody responses induced by vaccination against the human coronaviruses MERS-CoV and SARS-CoV-2
Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
Spike Dickus & Co : Geschichten von ganz besonderen Tieren
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
"SPiKe" ONE CoBRA GSE | NICH SAUBER MACHEN!!!!..
Emergence of SARS‐CoV‐2 spike protein at the vaccination site
Functional analysis of the MERS-coronavirus spike protein
"TMC" "SPiKE" "CoBRA"
Dance, politics & co-immunity
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
SARS-CoV-2 immunity through vaccination and infection in healthy individuals and haemodialysis patients
Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients
Characterization of B cell and antibody responses induced by vaccination against the human coronaviruses MERS-CoV and SARS-CoV-2
Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
Spike Dickus & Co : Geschichten von ganz besonderen Tieren
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects